Multicenter comparison of PEG-IFN alpha 2a or alpha 2b plus ribavirin for treatment-naive HCV patient in Korean population
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jin, Young-Joo | - |
dc.contributor.author | Lee, Jin-Woo | - |
dc.contributor.author | Lee, Jung Il | - |
dc.contributor.author | Park, Sang Hoon | - |
dc.contributor.author | Park, Choong Kee | - |
dc.contributor.author | Kim, Young Seok | - |
dc.contributor.author | Jeong, Sook-Hyang | - |
dc.contributor.author | Kim, Yun Soo | - |
dc.contributor.author | Kim, Ju Hyun | - |
dc.contributor.author | Hwang, Seong Gyu | - |
dc.contributor.author | Rim, Kyu Sung | - |
dc.contributor.author | Yim, Hyung Joon | - |
dc.contributor.author | Cheong, Jae Youn | - |
dc.contributor.author | Cho, Sung Won | - |
dc.contributor.author | Lee, June Sung | - |
dc.contributor.author | Park, Young Min | - |
dc.contributor.author | Jang, Jeong Won | - |
dc.contributor.author | Lee, Chun Kyon | - |
dc.contributor.author | Sohn, Joo Hyun | - |
dc.contributor.author | Yang, Jin Mo | - |
dc.contributor.author | Han, Seungbong | - |
dc.date.available | 2020-11-02T21:43:08Z | - |
dc.date.issued | 2013-04-29 | - |
dc.identifier.issn | 1471-230X | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/10798 | - |
dc.description.abstract | Background: Two recent Italian studies suggested that Pegylated-interferon (PEG-IFN) alfa-2a achieves a higher sustained virological response (SVR) rate than PEG-IFN alfa-2b. We intended to compare the efficacy and safety of PEG-IFN alfa-2a with those of PEG-IFN alfa-2b in Korean patients with chronic hepatitis C virus (HCV). Methods: This retrospective, multi-center trial was conducted on 661 treatment-naive chronic HCV patients. Patients received PEG-IFN alfa-2a (180 mu g/week; n=402) or PEG-IFN alfa-2b (1.5 mu g/kg/week; n=259) with ribavirin (800-1200 mg/day) for 24 or 48 weeks according to HCV genotypes. Results: Early virologic response and sustained virologic response (SVR) rates were not significantly different between two PEG-IFN groups both in patients with HCV genotype 1 (all P-values>0.05) and 2/3 (all P-values>0.05). SVR rates were not different between two groups in each categorized baseline characteristics: age (years) (<= 50 and >50), HCV viral load (IU/mL) (<= 7x10(5) and >7x10(5)), and hepatic fibrosis (F0-2 and F3-4) (all P-values >0.05). In additional analysis for 480 patients who sufficiently complied with treatment doses and duration (80/80/80 rule) and propensity-score matched analysis, SVR rates were not different between two groups both in patients with HCV genotype 1 and 2/3 (all P-values >0.05). Adverse event rates were similar between two groups. Conclusions: Unlike the Western data, efficacy and safety of PEG-IFN alfa-2a were similar to those of PEG-IFN alfa-2b in chronically HCV-infected Korean patients regardless of age, HCV viral load, and hepatic fibrosis. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | BIOMED CENTRAL LTD | - |
dc.title | Multicenter comparison of PEG-IFN alpha 2a or alpha 2b plus ribavirin for treatment-naive HCV patient in Korean population | - |
dc.type | Article | - |
dc.publisher.location | 영국 | - |
dc.identifier.doi | 10.1186/1471-230X-13-74 | - |
dc.identifier.scopusid | 2-s2.0-84876789373 | - |
dc.identifier.wosid | 000318506900002 | - |
dc.identifier.bibliographicCitation | BMC GASTROENTEROLOGY, v.13 | - |
dc.citation.title | BMC GASTROENTEROLOGY | - |
dc.citation.volume | 13 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | CHRONIC HEPATITIS-C | - |
dc.subject.keywordPlus | SUSTAINED VIROLOGICAL RESPONSE | - |
dc.subject.keywordPlus | PEGINTERFERON ALPHA-2A | - |
dc.subject.keywordPlus | VIRUS-INFECTION | - |
dc.subject.keywordPlus | COMBINATION THERAPY | - |
dc.subject.keywordPlus | RANDOMIZED-TRIAL | - |
dc.subject.keywordPlus | GENOTYPE-1 PATIENTS | - |
dc.subject.keywordPlus | (40 KD)/RIBAVIRIN | - |
dc.subject.keywordPlus | GENETIC-VARIATION | - |
dc.subject.keywordPlus | INTERFERON | - |
dc.subject.keywordAuthor | Chronic hepatitis C | - |
dc.subject.keywordAuthor | Pegylated interferon alfa-2a | - |
dc.subject.keywordAuthor | Pegylated interferon alfa-2b | - |
dc.subject.keywordAuthor | Ribavirin | - |
dc.subject.keywordAuthor | Sustained virological response | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.